| UniProt/SwissProt ID: | LEG3_HUMAN |
| Description: | lectin, galactoside-binding, soluble, 3 [Source:HGNC Symbol;Acc:6563] |
| Location: | chr14 q22.3 |
| Node attribute: | substrate |
| Phosphorylation site |
| Position | PhosphoPeptide | Catalytic kinase | Source |
|---|---|---|---|
| T175 | VIVCNtKLDNN | Gal-bind_lectin | PhosphoSitePlus |
| Y247 | LTSASyTMI__ | Gal-bind_lectin | PhosphoSitePlus |
| S12 | LHDALsGSGNP | CK1a(CK1 alpha | RegPhos |
| Y221 | AHLLQyNHRVK | Gal-bind_lectin | PhosphoSitePlus |
| S6 | MADNFsLHDAL | CK2a2 | RegPhos |
| S12 | LHDALsGSGNP | CK2a2 | RegPhos |
| S12 | LHDALsGSGNP | CK2a1 | RegPhos |
| Y79 | PAPGVyPGPPS | PhosphoSitePlus | |
| S12 | LHDALsGSGNP | CSNK2A2 | HPRD |
| S12 | LHDALsGSGNP | CSNK2A1 | HPRD |
| S12 | LHDALsGSGNP | CK1a | RegPhos |
| S12 | LHDALsGSGNP | CK2a1-rs | RegPhos |
| S6 | HDAL | CSNK1A1 | HPRD |
| S6 | HDAL | CSNK2A1 | HPRD |
| S6 | HDAL | CSNK2A2 | HPRD |
| S6 | HDAL | CK1_alpha | phosphoELM |
| S6 | MADNFsLHDAL | CK1a | RegPhos |
| S12 | LHDALsGSGNP | PhosphoSitePlus; RegPhos | |
| S6 | MADNFsLHDAL | CK2a1-rs | RegPhos |
| Y118 | PLIVPyNLPLP | Gal-bind_lectin | PhosphoSitePlus |
| S6 | MADNFsLHDAL | CK1a(CK1 alpha | RegPhos |
| S12 | LHDALsGSGNP | CK1_alpha | phosphoELM |
| S6 | MADNFsLHDAL | PhosphoSitePlus; RegPhos | |
| T133 | PRMLItILGTV | HPRD | |
| S6 | MADNFsLHDAL | CK2a1 | RegPhos |
| S12 | LHDALsGSGNP | CSNK1A1 | HPRD |
| Y107 | PATGPyGAPAG | PhosphoSitePlus | |
| Dephosphorylation site |
| LEG3_HUMAN do not have dephosphorylation site. |
| Mutation site |
| LEG3_HUMAN do not have mutation site. |
| Differential expressed protein |
| Ensembl ID | Cancer name | Design | Sample | Change | Ratio | Pubmed |
|---|---|---|---|---|---|---|
| ENSP00000254301 | Hepatocellular Carcinoma | Normal vs. Cancer | cell line | Down | 0.17 | 18646787 | ENSP00000254301 | Hepatocellular Carcinoma | Normal vs. Cancer | cell line | Down | 0.11 | 18646787 | ENSP00000254301 | papillary thyroid carcinoma | Normal vs. Cancer | tissue | Up | 2.3 | 16788983 | ENSP00000254301 | papillary thyroid carcinoma | Normal vs. Cancer | tissue | Up | 6 | 18665625 | ENSP00000254301 | papillary thyroid carcinoma | Normal vs. Cancer | tissue | Up | 3 | 18665625 | ENSP00000254301 | Non-small cell lung carcinoma | Metastasis | cell line | Up | 5.5 | 17418446 | ENSP00000254301 | Non-small cell lung carcinoma | Treatment (none vs CIGB-300 treatment) | cell line | Down | 0.4 | 20804217 | ENSP00000254301 | Breast Cancer | Normal vs. Cancer | cell line | Down | 0.65 | 20543960 | ENSP00000254301 | Breast Cancer | Normal vs. Cancer | cell line | Down | 0.73 | 20543960 | ENSP00000254301 | Breast Cancer | Normal vs. Cancer | cell line | Down | 0.71 | 20543960 | ENSP00000254301 | Breast Cancer | Normal vs. Cancer | tissue | Up | 20560667 | ENSP00000254301 | Ovarian Cancer | Treatment (Paclitaxel-sensitive vs. Paclitaxel-resistant) | cell line | Down | 0.32 | 18973835 | ENSP00000254301 | Ovarian Cancer | Treatment (Paclitaxel-sensitive vs. Paclitaxel-resistant) | cell line | Down | 0.23 | 18973835 | ENSP00000254301 | Ovarian Cancer | Treatment (Paclitaxel-sensitive vs. Paclitaxel-resistant) | cell line | Down | 0.33 | 19714814 | ENSP00000254301 | Ovarian Cancer | Treatment (Paclitaxel-sensitive vs. Paclitaxel-resistant) | cell line | Down | 0.62 | 19714814 | ENSP00000254301 | Ovarian Cancer | Treatment (Paclitaxel-sensitive vs. Paclitaxel-resistant) | cell line | Down | 0.71 | 19714814 | ENSP00000254301 | Pancreatic Cancer | Normal vs. Cancer | tissue | Up | 2 | 15526344 | ENSP00000254301 | Pancreatic Cancer | Normal vs. Cancer | tissue | Up | 420 | 19357035 |
| Hyperphosphorylation site |
| LEG3_HUMAN do not have hyperphosphorylation site. |
| Direct Interaction Pair |
| Source | Target | Relationship | Resource |
|---|---|---|---|
| ZAGL2_HUMAN | LEG3_HUMAN | kinase -> substrate | RegPhos |
| KC1A_HUMAN | LEG3_HUMAN | kinase -> substrate | HPRD; Robert H Newman (2013) |
| CSK21_HUMAN | LEG3_HUMAN | kinase -> substrate | HPRD |
| CSK22_HUMAN | LEG3_HUMAN | kinase -> substrate | HPRD |
| Function Annotation |
| KEGG Pathway |
| LEG3_HUMAN is not in KEGG pathway. |
| Gene Ontology |
| GO ID | GO_Term | Evidence | Ontology |
|---|---|---|---|
| GO:0005515 | protein binding | IPI | molecular_function |
| GO:0008380 | RNA splicing | IEA | biological_process |
| GO:0031012 | extracellular matrix | IDA | cellular_component |
| GO:0030154 | cell differentiation | IEA | biological_process |
| GO:0030246 | carbohydrate binding | IEA | molecular_function |
| GO:0005681 | spliceosomal complex | IEA | cellular_component |
| GO:0005737 | cytoplasm | IEA | cellular_component |
| GO:0005634 | nucleus | IEA | cellular_component |
| GO:0045087 | innate immune response | TAS | biological_process |
| GO:0005886 | plasma membrane | TAS | cellular_component |
| GO:0006397 | mRNA processing | IEA | biological_process |
| GO:0001501 | skeletal system development | IEA | biological_process |
| GO:0005578 | proteinaceous extracellular matrix | IEA | cellular_component |
| GO:0030198 | extracellular matrix organization | IEA | biological_process |
| GO:0005515 | protein binding | IEA | molecular_function |
| GO:0005743 | mitochondrial inner membrane | IDA | cellular_component |
| GO:0019863 | IgE binding | IEA | molecular_function |